IP Library Granted Patent US 11,840,552
Granted Patent B2
US 11,840,552 · App. 17/672,072 · Granted Dec 12, 2023

Iron compositions and methods of making and using the same

Inventors: Donald Jeffrey Keyser (Southlake, TX); Alvaro F. Guillem (Lantana, TX); Richard A. Zager (Seattle, WA)
Assignee: RENIBUS THERAPEUTICS, INC.
C07H23/00A61K9/0019A61K9/08A61K31/409
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,840,552
App. No.
17/672,072
Granted
Dec 12, 2023
Kind
B2
Abstract

The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.

Claims (11)

1. A method of intravenously administering an aqueous iron composition in a therapeutically effective amount, wherein the aqueous iron composition comprises:

iron sucrose;

bicarbonate; and

a pharmaceutically acceptable aqueous carrier,

wherein the iron sucrose is present in both iron (II) and iron (III) form and the iron sucrose has a M w according to Gel Permeation Chromatography (GPC) of between 33,000 and 38,000 Daltons.

2. The method of claim 1 , wherein the iron sucrose has a Mw according to GPC of between 33,000 and 35,000 Daltons.

3. The method of claim 1 , wherein the method further comprises administering a protoporphyrin.

4. The method of claim 1 , wherein the method further comprises administering tin protoporphyrin.

5. The method of claim 1 , wherein the composition is administered to treat a kidney disease or disorder.

6. The method of claim 5 , wherein the kidney disease or disorder is chronic kidney disease.

7. The method of claim 5 , wherein the composition treats iron deficiency associated with the kidney disease or disorder.

Assignments (2)
SECURITY INTEREST Recorded Jun 4, 2026
From: RENIBUS THERAPEUTICS, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 074858/0020 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2023
From: KEYSER, DONALD JEFFREY; GUILLEM, ALVARO F.; ZAGER, RICHARD A.
To: RENIBUS THERAPEUTICS, INC.
Reel/Frame 062828/0087 →
Continuity (3)
Continuation 16805223 · Feb 28, 2020
Provisional Application 62812028 · Feb 28, 2019
Related Publication 20220242901A1 · Aug 4, 2022